Catalog No.
DHD12612
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P15692
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
VGX200
Clone ID
VGX200
Note
For research use only. Not suitable for clinical or therapeutic use.
From pro-re-nata to fixed-interval regimen: evolving real-world treatment paradigms in anti-VEGF therapy for neovascular AMD., PMID:39881194
Divergent sex-specific pannexin-1 mechanisms in microglia and T cells underlie neuropathic pain., PMID:39892387
A Markov model assessing the cost-effectiveness of various anti-vascular endothelial growth factor drugs and panretinal photocoagulation for the treatment of proliferative diabetic retinopathy., PMID:39910280
Systemic counterregulatory response of angiopoietin-2 after intravitreal injections with faricimab for nAMD., PMID:39920326
Differential Effects of Retinol-Binding Protein 3 and Anti-VEGF Antibodies on Retinal Dysfunctions in Diabetic Retinopathy., PMID:39937209
Metabolomic Characteristics of Aqueous Humor in Wet Age-Related Macular Degeneration and the Impact of Anti-VEGF Treatment., PMID:39937494
The dual role of VEGF-A in a complex in vitro model of oxaliplatin-induced neurotoxicity: Pain-related and neuroprotective effects., PMID:39939241
Eliminating VEGFA+ tumor-associated neutrophils by antibody-drug conjugates boosts antitumor immunity and potentiates PD-1 immunotherapy in preclinical models of cervical cancer., PMID:39971940
Anti-VEGF monotherapy versus anti-VEGF therapy combined with laser or intravitreal glucocorticoid therapy for diabetic macular edema: A Bayesian network meta-analysis., PMID:39973301
DNA Framework-Enabled Ocular Barrier Penetration for Microinvasive Antiangiogenic Therapy., PMID:39979822
Use of a Convolutional Neural Network to Predict the Response of Diabetic Macular Edema to Intravitreal Anti-VEGF Treatment: A Pilot Study., PMID:39986639
Maternal F1 antibodies and cytokines in mother-neonate dog pairs in the Marmota himalayana plague focus., PMID:39991224
Developing transcriptomic biomarkers for TAVO412 utilizing next generation sequencing analyses of preclinical tumor models., PMID:39995668
Predictive Value of Circulatory Total VEGF-A and VEGF-A Isoforms for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small-Cell Lung Cancer., PMID:40002167
Faricimab-Associated Intraocular Inflammation With Features of Herpes Simplex Virus., PMID:40015591
Comparing safety and efficacy of Bevacizumab, Ranibizumab and Ranibizumab biosimilar in Retinopathy of prematurity., PMID:40016518
The 1-Step Versus 2-Step Subretinal Injection Trial (1,2-SIT)-A Randomized Controlled Trial to Compare Drug Reflux Following Subretinal Injection., PMID:40020980
Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial., PMID:40048178
Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial., PMID:40048197
Retinal Vascularization Rate Predicts Retinopathy of Prematurity and Remains Unaffected by Low-Dose Bevacizumab Treatment., PMID:40054545
Recurrence of neovascular age-related macular degeneration after discontinuation of modified treat and extend treatment., PMID:40089567
SIRE: Short interval in real life Does intensive anti-VEGF treatment in the first year predict subsequent treatment burden in exudative age-related macular degeneration?, PMID:40114029
Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD-1 and VEGF, in Chinese Patients With Advanced Solid Tumors., PMID:40114411
Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC., PMID:40121197
Long-term nucleus basalis cholinergic lesions alter the structure of cortical vasculature, astrocytic density and microglial activity in Wistar rats., PMID:40121723
Simultaneous inhibition of fibroblast growth factor-2 and vascular endothelial growth factor-a with RC28-E in diabetic macular edema: a phase 2 randomised trial., PMID:40122579
Identification and validation of hypoxia-responsive signature pathways in human cardiomyocytes., PMID:40177008
Mild antiresorptive activity of an anti-vascular endothelial growth factor A antibody and sunitinib in a rat model of bone resorption., PMID:40177629
Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma., PMID:40180668
[Morphological and functional changes of secondary macular neovascularization in central serous chorioretinopathy under anti-VEGF treatment]., PMID:40199756
Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes., PMID:40217902
Lymphangiogenesis in the Deepest Invasive Areas of Human Early-Stage Colorectal Cancer., PMID:40243510
Radiomics Analysis Based on Optical Coherence Tomography to Prognose the Efficacy of Anti-VEGF Therapy of Retinal Vein Occlusion-Related Macular Edema., PMID:40277425
Neuropilin-1: A Multifaceted Target for Cancer Therapy., PMID:40277760
Potential of autophagy in subretinal fibrosis in neovascular age-related macular degeneration., PMID:40307700
The role of biological macromolecules in the regulation of angiogenesis in glioblastoma: Focus on vascular growth factors, integrins, and extracellular matrix proteins., PMID:40319984
Combination therapy with cetirizine and anti-PD-1 antibody suppresses colitis-induced colon tumor formation in mice., PMID:40320111
Improved functional and morphological outcomes with faricimab in nAMD eyes with poor response to prior intravitreal anti-VEGF therapy., PMID:40338383
[Biosimilars of ranibizumab in retinal diseases: new possibilities in ophthalmology]., PMID:40353548
Unveiling the role of oxidative stress in ANCA-associated glomerulonephritis through integrated machine learning and bioinformatics analyses., PMID:40369957
Anti-CHI3L1 antibody suppresses colon cancer growth through downregulation of VEGFA and NAMPT expression., PMID:40377878
Efficacy and safety of prophylactic simultaneous intravitreal moxifloxacin injection with standard intravitreal anti-VEGF injection procedure in cases of cystoid macular edema and macular neovascularization., PMID:40405143
An Engineered Intravitreal Injection Retinal-Pigment-Epithelium-Tropic Adeno-Associated Virus Vector Expressing a Bispecific Antibody Binding VEGF-A and ANG-2 Rescues Neovascular Age-Related Macular Degeneration in Animal Models and Patients., PMID:40443830
A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models., PMID:40452841
Several Common Genetic Variations Associate With Functional or Anatomic Effects of Anti-VEGF Treatment in Conditions With Macular Edema., PMID:40455044
B7-H3 Exacerbates Laser-induced Choroidal Neovascularization by Promoting Macrophage Recruitment and Polarization via S100A8/A9., PMID:40456216
EFFICACY AND PROGNOSIS OF ANTI-VEGF AGENTS COMBINED WITH PANRETINAL PHOTOCOAGULATION IN DIABETIC RETINOPATHY: A CLINICAL OBSERVATIONAL STUDY., PMID:40466685
Clinical characteristics and treatment response of treatment requiring retinopathy of prematurity (ROP) in Big Premature Infants in Turkiye: BIG-ROP Study Group Report No 2 (BIG-ROP STUDY)., PMID:40473274
Monoclonal Antibodies Against Vascular Endothelial Growth Factor A (VEGF-A) Reduce Synovitis, Bone Damage, and Osteogenesis in an SKG Mouse Model of Spondyloarthritis., PMID:40487799
Advances in Molecular Imaging of VEGFRs: Innovations in Imaging and Therapeutics., PMID:40508182
For research use only. Not for human or drug use.
